Your Health, We Care
As a targeted drug for HER2 positive tumors, tucatinib has shown significant efficacy in the treatment of breast cancer and colorectal cancer.
In the MOUTIANEER clinical trial, the combination of tucatinib and trastuzumab in the treatment of HER2 positive metastatic colorectal cancer provided significant survival benefits for patients.
